Annexon (ANNX) Competitors $2.38 -0.22 (-8.46%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$2.40 +0.02 (+0.84%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANNX vs. AVDL, PAHC, PHVS, ARDX, GPCR, AMPH, VERV, SYRE, AKBA, and RCUSShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Pharvaris (PHVS), Ardelyx (ARDX), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Verve Therapeutics (VERV), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Its Competitors Avadel Pharmaceuticals Phibro Animal Health Pharvaris Ardelyx Structure Therapeutics Amphastar Pharmaceuticals Verve Therapeutics Spyre Therapeutics Akebia Therapeutics Arcus Biosciences Avadel Pharmaceuticals (NASDAQ:AVDL) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment. Which has preferable earnings & valuation, AVDL or ANNX? Avadel Pharmaceuticals has higher revenue and earnings than Annexon. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$169.12M7.72-$48.83M-$0.03-450.00AnnexonN/AN/A-$138.20M-$1.18-2.02 Is AVDL or ANNX more profitable? Annexon has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -1.32%. Avadel Pharmaceuticals' return on equity of -3.73% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-1.32% -3.73% -1.73% Annexon N/A -54.45%-46.56% Do analysts prefer AVDL or ANNX? Avadel Pharmaceuticals currently has a consensus target price of $18.67, indicating a potential upside of 38.27%. Annexon has a consensus target price of $12.50, indicating a potential upside of 425.21%. Given Annexon's higher probable upside, analysts clearly believe Annexon is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Annexon 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in AVDL or ANNX? 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 5.2% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, AVDL or ANNX? Avadel Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Does the media prefer AVDL or ANNX? In the previous week, Avadel Pharmaceuticals had 12 more articles in the media than Annexon. MarketBeat recorded 18 mentions for Avadel Pharmaceuticals and 6 mentions for Annexon. Annexon's average media sentiment score of 0.63 beat Avadel Pharmaceuticals' score of 0.49 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Annexon 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAvadel Pharmaceuticals beats Annexon on 9 of the 14 factors compared between the two stocks. Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$285.26M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-2.0220.4930.2725.74Price / SalesN/A356.37469.95115.79Price / CashN/A43.0338.2159.48Price / Book0.878.608.846.15Net Income-$138.20M-$54.65M$3.25B$265.06M7 Day Performance0.85%5.86%3.71%2.60%1 Month Performance-4.80%8.86%5.85%2.83%1 Year Performance-60.20%13.33%30.25%25.58% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon3.1834 of 5 stars$2.38-8.5%$12.50+425.2%-57.6%$285.26MN/A-2.0260News CoverageEarnings ReportAVDLAvadel Pharmaceuticals2.9304 of 5 stars$11.26+1.6%$18.33+62.8%-14.2%$1.07B$169.12M0.0070Positive NewsPAHCPhibro Animal Health3.7187 of 5 stars$27.14+3.9%$24.40-10.1%+75.8%$1.06B$1.02B13.531,940Positive NewsPHVSPharvaris2.4162 of 5 stars$21.24+6.2%$36.20+70.4%+36.0%$1.05BN/A0.0030News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionARDXArdelyx4.4259 of 5 stars$4.39+1.4%$10.88+147.7%+2.8%$1.04B$333.61M0.0090Options VolumeGPCRStructure Therapeutics2.487 of 5 stars$16.78-4.6%$76.17+353.9%-48.9%$1.01BN/A0.00136AMPHAmphastar Pharmaceuticals3.2228 of 5 stars$21.40+0.9%$32.33+51.1%-28.8%$999.82M$731.97M7.752,028Analyst UpgradeVERVVerve Therapeutics2.9638 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110SYRESpyre Therapeutics3.1236 of 5 stars$16.16-0.6%$53.40+230.4%-31.8%$980.08M$890K0.0073Positive NewsAKBAAkebia Therapeutics3.9862 of 5 stars$3.76+1.1%$6.75+79.5%+143.7%$977.01M$160.18M0.00430RCUSArcus Biosciences2.236 of 5 stars$9.22+0.6%$21.29+131.0%-32.1%$969.91M$258M0.00500 Related Companies and Tools Related Companies AVDL Competitors PAHC Competitors PHVS Competitors ARDX Competitors GPCR Competitors AMPH Competitors VERV Competitors SYRE Competitors AKBA Competitors RCUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANNX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access